Pregnancy-associated breast cancer

Cancer Journal

Volumn 11, Issue 2, 2005, Pages 83-95

  Psyrri, Amanda ^a   Burtness, Barbara ^a,b  

^a YALE CANCER CENTER   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast; Cancer; Chemotherapy; Pregnancy

Indexed keywords

ALKYLATING AGENT; ANTIMETABOLITE; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN; BRCA2 PROTEIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN; FLUOROURACIL; HALOPERIDOL; MELPHALAN; METHOTREXATE; MITOXANTRONE; MORPHINE SULFATE; NAVELBINE; ONDANSETRON; PACLITAXEL; PARACETAMOL; PAREGORIC; TAMOXIFEN; TRASTUZUMAB; VINBLASTINE; VINCRISTINE;

BIOEQUIVALENCE; BONE MARROW SUPPRESSION; BREAST BIOPSY; BREAST CANCER; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER PAIN; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CLINICAL FEATURE; CLINICAL TRIAL; CONGENITAL SKIN DISEASE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG INDUCED DISEASE; DRUG MECHANISM; FETAL METHOTREXATE SYNDROME; FETUS MALFORMATION; FETUS WASTAGE; FLUID RETENTION; GENE MUTATION; GENITAL MALFORMATION; GOLDENHAR SYNDROME; HIGH RISK POPULATION; HUMAN; INTRAUTERINE GROWTH RETARDATION; LEUKOPENIA; LOW BIRTH WEIGHT; MAMMOGRAPHY; MORTALITY; NAUSEA AND VOMITING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARIECTOMY; PATHOPHYSIOLOGY; PREGNANCY; PRENATAL EXPOSURE; PRIORITY JOURNAL; RADIATION EXPOSURE; RADIATION INJURY; REVIEW; SIDE EFFECT; SPONTANEOUS ABORTION; STILLBIRTH; THERAPEUTIC ABORTION; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME; ADULT; BREAST TUMOR; FEMALE; PATHOLOGY; PREGNANCY COMPLICATION; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; TIME;

ADULT; BREAST NEOPLASMS; FEMALE; HUMANS; NEOPLASM STAGING; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 23944454454     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/00130404-200503000-00001     Document Type: Review

References (117)

1. Pommier RF, Fields SA. Breast cancer in pregnancy: a diagnostic and therapeutic challenge. West J Med 1995;163:70-71.
2. Albrektsen G, Heuch I, Kvale G. The short-term and longterm effect of a pregnancy on breast cancer risk: a prospective study of 802,457 parous Norwegian women. Br J Cancer 1995;72:480-484.
3. von Schoultz E, Johansson H, Wilking N et al. Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol 1995;13:430-434.
4. Wallack MK, Wolf JA Jr, Bedwinek J et al. Gestational carcinoma of the female breast. Curr Probl Cancer 1983;7:1-58.
5. Saunders CM, Baum M. Breast cancer and pregnancy: a review. J R Soc Med 1993;86:162-165.
6. Anderson JM. Mammary cancers and pregnancy. Br Med J 1979;1:1124-1127.
7. Hassan I, Muhammed I, Attah MM et al. Breast cancer during pregnancy and lactation in Zaria, Nigeria. East Afr Med J 1995;72:280-282.
8. Petrek JA. Breast cancer and pregnancy. J Natl Cancer Inst Monogr 1994;16:113-121.
9. Lafreniere R. Bloody nipple discharge during pregnancy: a rationale for conservative treatment. J Surg Oncol 1990;43:228-230.
10. Kline TS, Lash S. Nipple secretion in pregnancy: a cytologic and histologic study. Am J Clin Pathol 1962;37:626-632.
11. King RM, Welch JS, Martin JK Jr et al. Carcinoma of the breast associated with pregnancy. Surg Gynecol Obstet 1985;160: 228-232.
12. White TT, White WC. Breast cancer and pregnancy: report of 49 cases followed 5 years. Ann Surg 1956;144:384-393.
13. Petrek JA, Dukoff R, Rogatko A. Prognosis of pregnancy-associated breast cancer. Cancer 1991;67:869-872.
14. Lloyd MS, Nash AG. "Occult" breast cancer. Ann R Coll Surg Engl 2001;83:420-424.
15. Jackson B, Scott-Conner C, Moulder J. Axillary metastasis from occult breast carcinoma: diagnosis and management. Am Surg 1995;61:431-434.
16. Olson JA Jr, Morris EA, Van Zee KJ et al. Magnetic resonance imaging facilitates breast conservation for occult breast cancer. Ann Surg Oncol 2000;7(6):411-415.
17. Tobin CE, Hendrix TM, Geyer SJ, Mendelson EB, Resnikoff LB. Breast imaging case of the day: lobular hyperplasia of pregnancy. Radiographics 1996;16:1225-1226.
18. Samuels TH, Liu FF, Yaffe M et al. Gestational breast cancer. Can Assoc Radiol J 1998;49:172-180.
19. Woo JC, Yu T, Hurd TC. Breast cancer in pregnancy: a literature review. Arch Surg 2003;138:91-98.
20. Liberman L, Giess CS, Dershaw DD et al. Imaging of pregnancy-associated breast cancer. Radiology 1994;191:245-248.
21. Berlin L. Radiation exposure and the pregnant patient. AJR Am J Roentgenol 1996;167:1377-1379.
22. McKnight AL, Kugel JL, Rossman PJ et al. MR elastography of breast cancer: preliminary results. AJR Am J Roentgenol 2002; 178:1411-1417.
23. Kanal E. Pregnancy and the safety of magnetic resonance imaging. Magn Reson Imaging Clin North Am 1994;2:309-317.
24. Byrd BF, Bayer DS, Robertson JC, Stephenson SE Jr. Treatment of breast tumors associated with pregnancy and lactation. Ann Surg 1962;155:940-947.
25. Ishida T, Yokoe T, Kasumi F et al. Clinicopathologic characteristics and prognosis of breast cancer patients associated with pregnancy and lactation: analysis of case-control study in Japan. Jpn J Cancer Res 1992;83:1143-1149.
26. Petrek JA. Breast cancer during pregnancy. Cancer 1994;74[1suppl]:518- 527.
27. Bunker JP, Houghton J, Baum M. Putting the risk of breast cancer in perspective. BMJ 1998;317:1307-1309.
28. Max MH, Klamer TW. Pregnancy and breast cancer. South Med J 1983;76:1088-1090.
29. Guinee VF, Olsson H, Moller T et al. Effect of pregnancy on prognosis for young women with breast cancer. Lancet 1994; 343:1587-1589.
30. Holdaway IM, Mason BH, Kay RG. Steroid hormone receptors in breast tumours presenting during pregnancy or lactation. J Surg Oncol 1984;25:38-41.
31. Elledge RM, Ciocca DR, Langone G et al. Estrogen receptor, progesterone receptor, and HER-2/neu protein in breast cancers from pregnant patients. Cancer 1993;71:2499-2506.
32. Budel V, Gasperin P, Hatschbach S et al. Ploidy level determination and quantitative chromatin pattern description in pregnancy-associated breast cancers. Breast Cancer Res Treat 1997;45:109-120.
33. Gwyn K, Theriault R. Breast cancer during pregnancy. Oncology (Huntingt) 2001;15:39-46; discussion 46, 49-51.
34. Borg A, Tandon AK, Sigurdsson H et al. HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 1990;50:4332-4337.
35. Schumacher M, Schmoor C, Sauerbrei W et al. The prognostic effect of histological tumor grade in node-negative breast cancer patients. Breast Cancer Res Treat 1993;25:235-245.
36. Shousha S. Breast carcinoma presenting during or shortly after pregnancy and lactation. Arch Pathol Lab Med 2000;124: 1053-1060.
37. Middleton LP, Amin M, Gwyn K et al. Breast carcinoma in pregnant women: assessment of clinicopathologic and immunohistochemical features. Cancer 2003;98:1055-1060.
38. Murphy KJ, Kazerooni EA, Braun MA et al. Radiographic appearance of intrathoracic complications of pregnancy. Can Assoc Radiol J 1996;47:453-459.
39. Pelsang RE. Diagnostic imaging modalities during pregnancy. Obstet Gynecol Clin North Am 1998;25:287-300.
40. Baker RR. Preoperative assessment of the patient with breast cancer. Surg Clin North Am 1984;64:1039-1050.
41. Gerber FH, Goodreau JJ, Kirchner PT et al. Efficacy of preoperative and postoperative bone scanning in the management of breast carcinoma. N Engl J Med 1977;297:300-303.
42. Stabin MG. Health concerns related to radiation exposure of the female nuclear medicine patient. Environ Health Perspect 1997;105[suppl 6]:1403-1409.
43. McKenzie AF, Budd RS, Yang C et al. Technetium-99m-methylene diphosphonate uptake in the fetal skeleton at 30 weeks gestation. J Nucl Med 1994;35:1338-1341.
44. Baker J, Ali A, Groch MW et al. Bone scanning in pregnant patients with breast carcinoma. Clin Nucl Med 1987;12:519-524.
45. Doll DC, Ringenberg QS, Yarbro JW. Management of cancer during pregnancy. Arch Intern Med 1988;148:2058-2064.
46. Hubay CA, Barry FM, Marr CC. Pregnancy and breast cancer. Surg Clin North Am 1978;58:819-831.
47. Wood JW, Johnson KG, Omori Y et al. Mental retardation in children exposed in utero to the atomic bombs in Hiroshima and Nagasaki. Am J Public Health Nations Health 1967;57: 1381-1389.
48. Otake M, Schull WJ. In utero exposure to A-bomb radiation and mental retardation: a reassessment. Br J Radiol 1984;57: 409-414.
49. Tabuchi A, Nakagawa S, Hirai T et al. Fetal hazards due to x-ray diagnosis during pregnancy. Hiroshima J Med Sci 1967; 16:49-66.
50. Jablon S, Kato H. Childhood cancer in relation to prenatal exposure to atomic-bomb radiation. Lancet 1970;2:1000-1003.
51. MacMahon B. Prenatal x-ray exposure and childhood cancer. J Natl Cancer Inst 1962;28:1173-1191.
52. Stewart A, Kneale GW. Radiation dose effects in relation to obstetric x-rays and childhood cancers. Lancet 1970;1:1185-1188.
53. Court-Brown WM, Doll R, Hill RB. Incidence of leukemia after exposure to diagnostic radiation in utero. Br Med J 1960;2:1539-1545.
54. Jablon S, Kato H. Childhood cancer in relation to prenatal exposure to atomic-bomb radiation. Lancet 1970;2:1000-1003.
55. Bloom AD, Neriishi S, Kamada N et al. Cytogenetic investigation of survivors of the atomic bombings of Hiroshima and Nagasaki. Lancet 1966;2:672-674.
56. Gustavson KH, Jagell S, Blomquist HK et al. Microcephaly, mental retardation and chromosomal aberrations in a girl following radiation therapy during late fetal life. Acta Radiol Oncol 1981;20:209-212.
57. Ricoul M, Dutrillaux B. [Chromosome hyper-radiosensitivity in mice at the end of pregnancy]. C R Acad Sci III 1991;312: 635-639.
58. Ricoul M, Sabatier L, Dutrillaux B. Increased chromosome radiosensitivity during pregnancy. Mutat Res 1997;374:73-78.
59. Stovall M, Blackwell CR, Cundiff J et al. Fetal dose from radiotherapy with photon beams: report of AAPM Radiation Therapy Committee Task Group No. 36. Med Phys 1995;22: 63-82.
60. Haagenson CD SA. Carcinoma of the breast: criteria of operability. Ann Surg 1943;118:859-870.
61. Zemlickis D, Lishner M, Degendorfer P et al. Maternal and fetal outcome after breast cancer in pregnancy. Am J Obstet Gynecol 1992;166:781-787.
62. Fisher B, Redmond C, Poisson R et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1989;320:822-828.
63. Kuerer HM, Gwyn K, Ames FC et al. Conservative surgery and chemotherapy for breast carcinoma during pregnancy. Surgery 2002;131:108-110.
64. Nicklas AH, Baker ME. Imaging strategies in the pregnant cancer patient. Semin Oncol 2000;27:623-632.
65. D'Ercole FJ, Scott D, Bell E et al. Paravertebral blockade for modified radical mastectomy in a pregnant patient. Anesth Analg 1999;88:1351-1353.
66. Mazze RI, Kallen B. Reproductive outcome after anesthesia and operation during pregnancy: a registry study of 5405 cases. Am J Obstet Gynecol 1989;161:1178-1185.
67. Gemignani ML, Petrek JA, Borgen PI. Breast cancer and pregnancy. Surg Clin North Am 1999;79:1157-1169.
68. Hasan C. FG, Schmolling J, Bode U. ASCO. Miami, FL; 1999.
69. Bonadonna G, Valagussa P, Moliterni A et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-906.
70. Stevenson J, Giantonio B, Boyd RL et al. Adjuvant chemotherapy for breast cancer in pregnancy: can recommendations be made with confidence. Semin Oncol 1997;24:xxv-xxxvi; discussion xxxvi, xxxix.
71. Arceci RJ, Croop JM, Horwitz SB et al. The gene encoding multidrug resistance is induced and expressed at high levels during pregnancy in the secretory epithelium of the uterus. Proc Natl Acad Sci USA 1988;85:4350-4354.
72. Smit JW, Huisman MT, van Tellingen O et al. Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J Clin Invest 1999;104: 1441-1447.
73. Doll DC, Ringenberg QS, Yarbro JW. Antineoplastic agents and pregnancy. Semin Oncol 1989;16:337-346.
74. Bawle EV, Conard JV, Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology 1998;57:51-55.
75. Ebert U, Loffler H, Kirch W. Cytotoxic therapy and pregnancy. Pharmacol Ther 1997;74:207-220.
76. Nagai H. Effects of transplacentally injected alkylating agents upon development of embryos: appearance of intrauterine death and mesodermal malformation. Bull Tokyo Dent Coll 1972;13:103-119.
77. Nettleton J, Long J, Kuban D et al. Breast cancer during pregnancy: quantifying the risk of treatment delay. Obstet Gynecol 1996;87:414-418.
78. DeLoia JA, Stewart-Akers AM, Creinin MD. Effects of methotrexate on trophoblast proliferation and local immune responses. Hum Reprod 1998;13:1063-1069.
79. Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicin- cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483-1496.
80. Berry DL, Theriault RL, Holmes FA et al. Management of breast cancer during pregnancy using a standardized protocol. J Clin Oncol 1999;17:855-861.
81. Giacalone PL, Laffargue F, Benos P. Chemotherapy for breast carcinoma during pregnancy: a French national survey. Cancer 1999;86:2266-2272.
82. Reynoso EE, Shepherd FA, Messner HA et al. Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents. J Clin Oncol 1987;5:1098-1106.
83. MacDougall MK, LeGrand SB, Walsh D. Symptom control in the pregnant cancer patient. Semin Oncol 2000;27:704-711.
84. Burtness B, Windsor S, Holston B et al. Adjuvant sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide (ATC) for high-risk breast cancer is feasible in the community setting. Cancer J Sci Am 1999;5:224-229.
85. De Santis M, Lucchese A, De Carolis S et al. Metastatic breast cancer in pregnancy: first case of chemotherapy with docetaxel. Eur J Cancer Care (Engl) 2000;9:235-237.
86. Cullins SL, Pridjian G, Sutherland CM. Goldenhar's syndrome associated with tamoxifen given to the mother during gestation. JAMA 1994;271:1905-1906.
87. Tewari K, Bonebrake RG, Asrat T et al. Ambiguous genitalia in infant exposed to tamoxifen in utero. Lancet 1997;350:183.
88. Isaacs JH. Cancer of the breast in pregnancy. Surg Clin North Am 1995;75:47-51.
89. Baum M, Ziv Y, Colletta A. Prospects for the chemoprevention of breast cancer. Br Med Bull 1991;47:493-503.
90. Cunha GR, Taguchi O, Namikawa R et al. Teratogenic effects of clomiphene, tamoxifen, and diethylstilbestrol on the developing human female genital tract. Hum Pathol 1987;18: 1132-1143.
91. Fox R. Breast cancer and pregnancy. J R Soc Med 1993;86:743.
92. Cobleigh MA, Vogel CL, Tripathy D et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:2639-2648.
93. Mielke S, Meden H, Kuhn W. Expression of the c-erbB-2-encoded oncoprotein p185 (HER-2/neu) in pregnancy as a model for oncogene-induced carcinogenesis. Med Hypotheses 1998;50:359-362.
94. Applewhite RR, Smith LR, DiVincenti F. Carcinoma of the breast associated with pregnancy and lactation. Am Surg 1973;39:101-104.
95. Bonnier P, Romain S, Dilhuydy JM et al. Influence of pregnancy on the outcome of breast cancer: a case-control study. Societe Francaise de Senologie et de Pathologie Mammaire Study Group. Int J Cancer 1997;72:720-727.
96. Tretli S, Kvalheim G, Thoresen S et al. Survival of breast cancer patients diagnosed during pregnancy or lactation. Br J Cancer 1988;58:382-384.
97. Phillips KA, Milne RL, Friedlander ML et al. Prognosis of premenopausal breast cancer and childbirth prior to diagnosis. J Clin Oncol 2004;22:699-705.
98. Marquis ST, Rajan JV, Wynshaw-Boris A et al. The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues. Nat Genet 1995;11:17-26.
99. Russo J, Tay LK, Russo IH. Differentiation of the mammary gland and susceptibility to carcinogenesis. Breast Cancer Res Treat 1982;2:5-73.
100. Russo J, Russo IH. Toward a physiological approach to breast cancer prevention. Cancer Epidemiol Biomarkers Prev 1994; 3:353-364.
101. Jernstrom H, Lerman C, Ghadirian P et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet 1999;354:1846-1850.
102. Preston-Martin S, Pike MC, Ross RK et al. Increased cell division as a cause of human cancer. Cancer Res 1990;50:7415-7421.
103. Rajan JV, Wang M, Marquis ST et al. Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. Proc Natl Acad Sci USA 1996;93: 13078-13083.
104. Grabrick DM, Hartmann LC, Cerhan JR et al. Risk of breast cancer with oral contraceptive use in women with a family history of breast cancer. JAMA 2000;284:1791-1798.
105. Ursin G, Henderson BE, Haile RW et al. Does oral contraceptive use increase the risk of breast cancer in women with BRCA1/BRCA2 mutations more than in other women? Cancer Res 1997;57:3678-3681.
106. Shen T, Vortmeyer AO, Zhuang Z et al. High frequency of allelic loss of BRCA2 gene in pregnancy-associated breast carcinoma. J Natl Cancer Inst 1999;91:1686-1687.
107. Johannsson O, Loman N, Borg A et al. Pregnancy-associated breast cancer in BRCA1 and BRCA2 germline mutation carriers. Lancet 1998;352:1359-1360.
108. Velentgas P, Daling JR, Malone KE et al. Pregnancy after breast carcinoma: outcomes and influence on mortality. Cancer 1999;85:2424-2432.
109. Gelber S, Coates AS, Goldhirsch A et al. Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer. J Clin Oncol 2001;19:1671-1675.
110. Clark RM, Reid J. Carinoma of the breast in pregnancy and lactation. Int J Radiat Oncol Biol Phys 1978;4:693-698.
111. Cooper DR, Butterfield J. Pregnancy subsequent to mastectomy for cancer of the breast. Ann Surg 1970;171:429-433.
112. Danforth DN Jr. How subsequent pregnancy affects outcome in women with a prior breast cancer. Oncology (Huntingt) 1991;5:23-30; discussion 30-31, 35.
113. Kroman N, Wohlfahrt J, Andersen KW et al. Time since childbirth and prognosis in primary breast cancer: population based study. BMJ 1997;315:851-855.
114. Lozada J, Hoy E and the M.D. Anderson Cancer Center, Houston, TX. Effects of pregnancy following treatment for breast cancer on survival and risk of recurrence. ASCO; 2001.
115. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists' Collaborative Group. Lancet 1992;339:71-85.
116. Sutton R, Buzdar AU, Hortobagyi GN. Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. Cancer 1990;65:847-850.
117. Nugent P, O'Connell TX. Breast cancer and pregnancy. Arch Surg 1985;120:1221-1224.